nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP1A2—Carmustine—lymphatic system cancer	0.091	0.131	CbGbCtD
Fluvoxamine—CYP3A5—Teniposide—lymphatic system cancer	0.0822	0.118	CbGbCtD
Fluvoxamine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.074	0.106	CbGbCtD
Fluvoxamine—CYP2C19—Teniposide—lymphatic system cancer	0.0663	0.0954	CbGbCtD
Fluvoxamine—CYP2C9—Teniposide—lymphatic system cancer	0.0551	0.0793	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0527	0.0759	CbGbCtD
Fluvoxamine—CYP3A7—Vincristine—lymphatic system cancer	0.0527	0.0759	CbGbCtD
Fluvoxamine—CYP3A5—Vincristine—lymphatic system cancer	0.0395	0.0569	CbGbCtD
Fluvoxamine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0374	0.0538	CbGbCtD
Fluvoxamine—CYP3A4—Cytarabine—lymphatic system cancer	0.0325	0.0468	CbGbCtD
Fluvoxamine—CYP3A4—Teniposide—lymphatic system cancer	0.032	0.0461	CbGbCtD
Fluvoxamine—ABCB1—Vincristine—lymphatic system cancer	0.0257	0.0371	CbGbCtD
Fluvoxamine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0224	0.0323	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—lymphatic system cancer	0.0156	0.0224	CbGbCtD
Fluvoxamine—CYP3A4—Vincristine—lymphatic system cancer	0.0154	0.0222	CbGbCtD
Fluvoxamine—Infection—Bleomycin—lymphatic system cancer	0.000316	0.00103	CcSEcCtD
Fluvoxamine—Anaemia—Carmustine—lymphatic system cancer	0.000314	0.00103	CcSEcCtD
Fluvoxamine—Back pain—Vincristine—lymphatic system cancer	0.000314	0.00103	CcSEcCtD
Fluvoxamine—Vomiting—Teniposide—lymphatic system cancer	0.000314	0.00103	CcSEcCtD
Fluvoxamine—Agitation—Carmustine—lymphatic system cancer	0.000313	0.00102	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000311	0.00102	CcSEcCtD
Fluvoxamine—Asthenia—Fludarabine—lymphatic system cancer	0.000311	0.00102	CcSEcCtD
Fluvoxamine—Rash—Teniposide—lymphatic system cancer	0.000311	0.00102	CcSEcCtD
Fluvoxamine—Dermatitis—Teniposide—lymphatic system cancer	0.000311	0.00102	CcSEcCtD
Fluvoxamine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00031	0.00101	CcSEcCtD
Fluvoxamine—Headache—Teniposide—lymphatic system cancer	0.000309	0.00101	CcSEcCtD
Fluvoxamine—Pruritus—Fludarabine—lymphatic system cancer	0.000307	0.001	CcSEcCtD
Fluvoxamine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000307	0.001	CcSEcCtD
Fluvoxamine—Back pain—Mitoxantrone—lymphatic system cancer	0.000306	0.001	CcSEcCtD
Fluvoxamine—Leukopenia—Carmustine—lymphatic system cancer	0.000304	0.000997	CcSEcCtD
Fluvoxamine—Anorexia—Bleomycin—lymphatic system cancer	0.000303	0.000992	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000301	0.000985	CcSEcCtD
Fluvoxamine—Anaemia—Vincristine—lymphatic system cancer	0.0003	0.000982	CcSEcCtD
Fluvoxamine—Agitation—Vincristine—lymphatic system cancer	0.000298	0.000977	CcSEcCtD
Fluvoxamine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000298	0.000976	CcSEcCtD
Fluvoxamine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000298	0.000975	CcSEcCtD
Fluvoxamine—Polyuria—Methotrexate—lymphatic system cancer	0.000298	0.000975	CcSEcCtD
Fluvoxamine—Hypotension—Bleomycin—lymphatic system cancer	0.000297	0.000973	CcSEcCtD
Fluvoxamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000297	0.000972	CcSEcCtD
Fluvoxamine—Convulsion—Carmustine—lymphatic system cancer	0.000295	0.000965	CcSEcCtD
Fluvoxamine—Hypertension—Carmustine—lymphatic system cancer	0.000294	0.000961	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000293	0.000961	CcSEcCtD
Fluvoxamine—Nausea—Teniposide—lymphatic system cancer	0.000293	0.00096	CcSEcCtD
Fluvoxamine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000292	0.000957	CcSEcCtD
Fluvoxamine—Vertigo—Vincristine—lymphatic system cancer	0.000292	0.000955	CcSEcCtD
Fluvoxamine—Leukopenia—Vincristine—lymphatic system cancer	0.000291	0.000951	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00029	0.000949	CcSEcCtD
Fluvoxamine—Myalgia—Carmustine—lymphatic system cancer	0.00029	0.000948	CcSEcCtD
Fluvoxamine—Chest pain—Carmustine—lymphatic system cancer	0.00029	0.000948	CcSEcCtD
Fluvoxamine—Anxiety—Carmustine—lymphatic system cancer	0.000289	0.000945	CcSEcCtD
Fluvoxamine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000286	0.000935	CcSEcCtD
Fluvoxamine—Malaise—Mitoxantrone—lymphatic system cancer	0.000285	0.000934	CcSEcCtD
Fluvoxamine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000284	0.000928	CcSEcCtD
Fluvoxamine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000283	0.000928	CcSEcCtD
Fluvoxamine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000283	0.000927	CcSEcCtD
Fluvoxamine—Convulsion—Vincristine—lymphatic system cancer	0.000281	0.000921	CcSEcCtD
Fluvoxamine—Hypertension—Vincristine—lymphatic system cancer	0.00028	0.000918	CcSEcCtD
Fluvoxamine—Confusional state—Carmustine—lymphatic system cancer	0.00028	0.000916	CcSEcCtD
Fluvoxamine—Oedema—Carmustine—lymphatic system cancer	0.000278	0.000909	CcSEcCtD
Fluvoxamine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000277	0.000908	CcSEcCtD
Fluvoxamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000276	0.000905	CcSEcCtD
Fluvoxamine—Myalgia—Vincristine—lymphatic system cancer	0.000276	0.000905	CcSEcCtD
Fluvoxamine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000276	0.000904	CcSEcCtD
Fluvoxamine—Cough—Mitoxantrone—lymphatic system cancer	0.000276	0.000903	CcSEcCtD
Fluvoxamine—Infection—Carmustine—lymphatic system cancer	0.000276	0.000903	CcSEcCtD
Fluvoxamine—Vomiting—Fludarabine—lymphatic system cancer	0.000276	0.000903	CcSEcCtD
Fluvoxamine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000274	0.000897	CcSEcCtD
Fluvoxamine—Rash—Fludarabine—lymphatic system cancer	0.000273	0.000895	CcSEcCtD
Fluvoxamine—Dermatitis—Fludarabine—lymphatic system cancer	0.000273	0.000894	CcSEcCtD
Fluvoxamine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000273	0.000894	CcSEcCtD
Fluvoxamine—Pain—Bleomycin—lymphatic system cancer	0.000272	0.00089	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000272	0.00089	CcSEcCtD
Fluvoxamine—Headache—Fludarabine—lymphatic system cancer	0.000272	0.00089	CcSEcCtD
Fluvoxamine—Tachycardia—Carmustine—lymphatic system cancer	0.000271	0.000887	CcSEcCtD
Fluvoxamine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000269	0.000881	CcSEcCtD
Fluvoxamine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000269	0.000881	CcSEcCtD
Fluvoxamine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000269	0.000881	CcSEcCtD
Fluvoxamine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000268	0.000878	CcSEcCtD
Fluvoxamine—Lethargy—Methotrexate—lymphatic system cancer	0.000267	0.000874	CcSEcCtD
Fluvoxamine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000267	0.000874	CcSEcCtD
Fluvoxamine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000266	0.000871	CcSEcCtD
Fluvoxamine—Oedema—Vincristine—lymphatic system cancer	0.000265	0.000868	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000265	0.000868	CcSEcCtD
Fluvoxamine—Anorexia—Carmustine—lymphatic system cancer	0.000265	0.000866	CcSEcCtD
Fluvoxamine—Infection—Vincristine—lymphatic system cancer	0.000263	0.000862	CcSEcCtD
Fluvoxamine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000262	0.000858	CcSEcCtD
Fluvoxamine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000262	0.000856	CcSEcCtD
Fluvoxamine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00026	0.000852	CcSEcCtD
Fluvoxamine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00026	0.000851	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000259	0.000849	CcSEcCtD
Fluvoxamine—Hypotension—Carmustine—lymphatic system cancer	0.000259	0.000849	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000258	0.000845	CcSEcCtD
Fluvoxamine—Oedema—Mitoxantrone—lymphatic system cancer	0.000258	0.000845	CcSEcCtD
Fluvoxamine—Nausea—Fludarabine—lymphatic system cancer	0.000258	0.000843	CcSEcCtD
Fluvoxamine—Infection—Mitoxantrone—lymphatic system cancer	0.000256	0.000839	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000256	0.000839	CcSEcCtD
Fluvoxamine—Shock—Mitoxantrone—lymphatic system cancer	0.000254	0.000831	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000253	0.000828	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000253	0.000827	CcSEcCtD
Fluvoxamine—Urticaria—Bleomycin—lymphatic system cancer	0.000253	0.000827	CcSEcCtD
Fluvoxamine—Anorexia—Vincristine—lymphatic system cancer	0.000253	0.000827	CcSEcCtD
Fluvoxamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000252	0.000825	CcSEcCtD
Fluvoxamine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000251	0.000823	CcSEcCtD
Fluvoxamine—Insomnia—Carmustine—lymphatic system cancer	0.000251	0.000822	CcSEcCtD
Fluvoxamine—Irritability—Methotrexate—lymphatic system cancer	0.00025	0.000817	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000249	0.000817	CcSEcCtD
Fluvoxamine—Paraesthesia—Carmustine—lymphatic system cancer	0.000249	0.000816	CcSEcCtD
Fluvoxamine—Mood swings—Methotrexate—lymphatic system cancer	0.000248	0.000811	CcSEcCtD
Fluvoxamine—Hypotension—Vincristine—lymphatic system cancer	0.000248	0.000811	CcSEcCtD
Fluvoxamine—Dyspnoea—Carmustine—lymphatic system cancer	0.000247	0.00081	CcSEcCtD
Fluvoxamine—Somnolence—Carmustine—lymphatic system cancer	0.000247	0.000808	CcSEcCtD
Fluvoxamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000246	0.000805	CcSEcCtD
Fluvoxamine—Ataxia—Methotrexate—lymphatic system cancer	0.000246	0.000805	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000242	0.000791	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000241	0.00079	CcSEcCtD
Fluvoxamine—Decreased appetite—Carmustine—lymphatic system cancer	0.000241	0.00079	CcSEcCtD
Fluvoxamine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000241	0.000789	CcSEcCtD
Fluvoxamine—Insomnia—Vincristine—lymphatic system cancer	0.00024	0.000785	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00024	0.000785	CcSEcCtD
Fluvoxamine—Paraesthesia—Vincristine—lymphatic system cancer	0.000238	0.000779	CcSEcCtD
Fluvoxamine—Pain—Carmustine—lymphatic system cancer	0.000237	0.000777	CcSEcCtD
Fluvoxamine—Constipation—Carmustine—lymphatic system cancer	0.000237	0.000777	CcSEcCtD
Fluvoxamine—Breast disorder—Methotrexate—lymphatic system cancer	0.000236	0.000774	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000236	0.000771	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000235	0.00077	CcSEcCtD
Fluvoxamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000234	0.000767	CcSEcCtD
Fluvoxamine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000232	0.000759	CcSEcCtD
Fluvoxamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00023	0.000754	CcSEcCtD
Fluvoxamine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00023	0.000753	CcSEcCtD
Fluvoxamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000229	0.000751	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000229	0.000749	CcSEcCtD
Fluvoxamine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000229	0.000749	CcSEcCtD
Fluvoxamine—Fatigue—Vincristine—lymphatic system cancer	0.000228	0.000748	CcSEcCtD
Fluvoxamine—Asthenia—Bleomycin—lymphatic system cancer	0.000228	0.000747	CcSEcCtD
Fluvoxamine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000227	0.000744	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000227	0.000743	CcSEcCtD
Fluvoxamine—Pain—Vincristine—lymphatic system cancer	0.000227	0.000742	CcSEcCtD
Fluvoxamine—Constipation—Vincristine—lymphatic system cancer	0.000227	0.000742	CcSEcCtD
Fluvoxamine—Asthma—Methotrexate—lymphatic system cancer	0.000226	0.00074	CcSEcCtD
Fluvoxamine—Pruritus—Bleomycin—lymphatic system cancer	0.000225	0.000737	CcSEcCtD
Fluvoxamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000224	0.000734	CcSEcCtD
Fluvoxamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000222	0.000728	CcSEcCtD
Fluvoxamine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000222	0.000726	CcSEcCtD
Fluvoxamine—Pain—Mitoxantrone—lymphatic system cancer	0.000221	0.000722	CcSEcCtD
Fluvoxamine—Constipation—Mitoxantrone—lymphatic system cancer	0.000221	0.000722	CcSEcCtD
Fluvoxamine—Body temperature increased—Carmustine—lymphatic system cancer	0.000219	0.000718	CcSEcCtD
Fluvoxamine—Abdominal pain—Carmustine—lymphatic system cancer	0.000219	0.000718	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000217	0.00071	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000217	0.000709	CcSEcCtD
Fluvoxamine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000213	0.000696	CcSEcCtD
Fluvoxamine—Dysuria—Methotrexate—lymphatic system cancer	0.000211	0.000692	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000211	0.000691	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00021	0.000688	CcSEcCtD
Fluvoxamine—Abdominal pain—Vincristine—lymphatic system cancer	0.000209	0.000686	CcSEcCtD
Fluvoxamine—Body temperature increased—Vincristine—lymphatic system cancer	0.000209	0.000686	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000208	0.000682	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000206	0.000676	CcSEcCtD
Fluvoxamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000205	0.000671	CcSEcCtD
Fluvoxamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000205	0.00067	CcSEcCtD
Fluvoxamine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000204	0.000668	CcSEcCtD
Fluvoxamine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000204	0.000668	CcSEcCtD
Fluvoxamine—Pneumonia—Methotrexate—lymphatic system cancer	0.000203	0.000664	CcSEcCtD
Fluvoxamine—Vomiting—Bleomycin—lymphatic system cancer	0.000202	0.000662	CcSEcCtD
Fluvoxamine—Drowsiness—Methotrexate—lymphatic system cancer	0.000202	0.00066	CcSEcCtD
Fluvoxamine—Depression—Methotrexate—lymphatic system cancer	0.000201	0.000658	CcSEcCtD
Fluvoxamine—Rash—Bleomycin—lymphatic system cancer	0.000201	0.000656	CcSEcCtD
Fluvoxamine—Dermatitis—Bleomycin—lymphatic system cancer	0.0002	0.000656	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.0002	0.000654	CcSEcCtD
Fluvoxamine—Asthenia—Carmustine—lymphatic system cancer	0.000199	0.000652	CcSEcCtD
Fluvoxamine—Renal failure—Methotrexate—lymphatic system cancer	0.000198	0.000649	CcSEcCtD
Fluvoxamine—Stomatitis—Methotrexate—lymphatic system cancer	0.000197	0.000643	CcSEcCtD
Fluvoxamine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000196	0.000642	CcSEcCtD
Fluvoxamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000195	0.000639	CcSEcCtD
Fluvoxamine—Sweating—Methotrexate—lymphatic system cancer	0.000193	0.000633	CcSEcCtD
Fluvoxamine—Haematuria—Methotrexate—lymphatic system cancer	0.000192	0.000629	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000191	0.000624	CcSEcCtD
Fluvoxamine—Epistaxis—Methotrexate—lymphatic system cancer	0.00019	0.000623	CcSEcCtD
Fluvoxamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00019	0.000622	CcSEcCtD
Fluvoxamine—Asthenia—Vincristine—lymphatic system cancer	0.00019	0.000622	CcSEcCtD
Fluvoxamine—Diarrhoea—Carmustine—lymphatic system cancer	0.00019	0.000622	CcSEcCtD
Fluvoxamine—Nausea—Bleomycin—lymphatic system cancer	0.000189	0.000618	CcSEcCtD
Fluvoxamine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000188	0.000616	CcSEcCtD
Fluvoxamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000185	0.000606	CcSEcCtD
Fluvoxamine—Dizziness—Carmustine—lymphatic system cancer	0.000184	0.000601	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000182	0.000596	CcSEcCtD
Fluvoxamine—Diarrhoea—Vincristine—lymphatic system cancer	0.000181	0.000594	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000181	0.000592	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—lymphatic system cancer	0.000181	0.000592	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00018	0.000588	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000179	0.000585	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000177	0.000581	CcSEcCtD
Fluvoxamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000177	0.000578	CcSEcCtD
Fluvoxamine—Vomiting—Carmustine—lymphatic system cancer	0.000176	0.000578	CcSEcCtD
Fluvoxamine—Dizziness—Vincristine—lymphatic system cancer	0.000175	0.000574	CcSEcCtD
Fluvoxamine—Rash—Carmustine—lymphatic system cancer	0.000175	0.000573	CcSEcCtD
Fluvoxamine—Dermatitis—Carmustine—lymphatic system cancer	0.000175	0.000572	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—lymphatic system cancer	0.000174	0.000571	CcSEcCtD
Fluvoxamine—Headache—Carmustine—lymphatic system cancer	0.000174	0.000569	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000171	0.00056	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—lymphatic system cancer	0.000169	0.000554	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—lymphatic system cancer	0.000169	0.000552	CcSEcCtD
Fluvoxamine—Vomiting—Vincristine—lymphatic system cancer	0.000168	0.000552	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000168	0.00055	CcSEcCtD
Fluvoxamine—Rash—Vincristine—lymphatic system cancer	0.000167	0.000547	CcSEcCtD
Fluvoxamine—Dermatitis—Vincristine—lymphatic system cancer	0.000167	0.000546	CcSEcCtD
Fluvoxamine—Headache—Vincristine—lymphatic system cancer	0.000166	0.000543	CcSEcCtD
Fluvoxamine—Nausea—Carmustine—lymphatic system cancer	0.000165	0.00054	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—lymphatic system cancer	0.000164	0.000538	CcSEcCtD
Fluvoxamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000164	0.000537	CcSEcCtD
Fluvoxamine—Rash—Mitoxantrone—lymphatic system cancer	0.000163	0.000533	CcSEcCtD
Fluvoxamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000163	0.000532	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—lymphatic system cancer	0.000162	0.000532	CcSEcCtD
Fluvoxamine—Headache—Mitoxantrone—lymphatic system cancer	0.000162	0.000529	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—lymphatic system cancer	0.00016	0.000524	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—lymphatic system cancer	0.000159	0.000519	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—lymphatic system cancer	0.000158	0.000516	CcSEcCtD
Fluvoxamine—Nausea—Vincristine—lymphatic system cancer	0.000157	0.000515	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000154	0.000505	CcSEcCtD
Fluvoxamine—Nausea—Mitoxantrone—lymphatic system cancer	0.000153	0.000502	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—lymphatic system cancer	0.000152	0.000499	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—lymphatic system cancer	0.000148	0.000486	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000146	0.000479	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—lymphatic system cancer	0.000146	0.000477	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—lymphatic system cancer	0.000142	0.000465	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—lymphatic system cancer	0.000142	0.000463	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—lymphatic system cancer	0.000141	0.000462	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—lymphatic system cancer	0.000137	0.00045	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—lymphatic system cancer	0.000136	0.000447	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—lymphatic system cancer	0.000134	0.000439	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—lymphatic system cancer	0.000134	0.000439	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—lymphatic system cancer	0.000134	0.000439	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—lymphatic system cancer	0.000133	0.000434	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—lymphatic system cancer	0.00013	0.000424	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000129	0.000421	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—lymphatic system cancer	0.000128	0.000418	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000126	0.000413	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000126	0.000412	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000124	0.000407	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—lymphatic system cancer	0.000123	0.000401	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—lymphatic system cancer	0.00012	0.000393	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000117	0.000384	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—lymphatic system cancer	0.000116	0.000381	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000115	0.000378	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000115	0.000375	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—lymphatic system cancer	0.000114	0.000374	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000113	0.000371	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000112	0.000366	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000111	0.000363	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—lymphatic system cancer	0.000111	0.000363	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—lymphatic system cancer	0.00011	0.00036	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000106	0.000347	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000105	0.000344	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—lymphatic system cancer	0.000102	0.000334	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000102	0.000333	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000102	0.000333	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—lymphatic system cancer	9.47e-05	0.00031	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—lymphatic system cancer	9.22e-05	0.000302	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—lymphatic system cancer	9.1e-05	0.000298	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—lymphatic system cancer	8.8e-05	0.000288	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—lymphatic system cancer	8.5e-05	0.000278	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—lymphatic system cancer	8.17e-05	0.000268	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—lymphatic system cancer	8.11e-05	0.000265	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—lymphatic system cancer	8.1e-05	0.000265	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—lymphatic system cancer	8.05e-05	0.000264	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—lymphatic system cancer	7.64e-05	0.00025	CcSEcCtD
